Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Ultromics found in HSH's search of the last 24 months. Jul 2025: the company raised $55m in Series C funding to expand its AI heart failure diagnostics.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Ultromics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, safety notices or warning letters involving Ultromics or its EchoGo products found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No notable NHS contract awards, troubled implementations or customer disputes involving Ultromics found in HSH's search of the last 24 months.